Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

AZD 6244 19trametinib 5Lovastatin 5Deoxycholic Acid 4mirdametinib 3Lasers, Solid-State 3pirfenidone 2fludarabine 2binimetinib 2Vincristine 2Vinblastine 2Transcranial Direct Current Stimulation 2Specimen Handling 2Sirolimus 2Polidocanol 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Lasers 2Lamotrigine 2Inhalation 2Everolimus 2Carboplatin 2Biopsy 2Acetylcysteine 2tipifarnib 1thymoglobulin 1talimogene laherparepvec 1pomalidomide 1peginterferon alfa-2b 1omipalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibromatosis 1 × Lenalidomide × Clear all
NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled 17 charts
CNS

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡